A5040929183- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Viral-associated cancers and disorders
- CAR-T cell therapy research
- Glioma Diagnosis and Treatment
- Neuroblastoma Research and Treatments
- Cancer-related Molecular Pathways
- CNS Lymphoma Diagnosis and Treatment
- Melanoma and MAPK Pathways
- Cancer Cells and Metastasis
- Sarcoma Diagnosis and Treatment
- HER2/EGFR in Cancer Research
- Hippo pathway signaling and YAP/TAZ
- Colorectal and Anal Carcinomas
- Lung Cancer Treatments and Mutations
- Cancer Genomics and Diagnostics
- Neurofibromatosis and Schwannoma Cases
- Immune Cell Function and Interaction
- Oral and Craniofacial Lesions
- Virus-based gene therapy research
- Ubiquitin and proteasome pathways
- Salivary Gland Tumors Diagnosis and Treatment
- Tumors and Oncological Cases
- Oral and Maxillofacial Pathology
- Renal and related cancers
Dmitry Rogachev National Research Center of Pediatric Hematology, Oncology and Immunology
2021-2025
Russian Cancer Research Center NN Blokhin
2025
Ministry of Health of the Russian Federation
2022-2024
Peoples' Friendship University of Russia
2024
National Medical Research Center of Cardiology
2022
Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare cancer, and large international cooperative efforts are needed to evaluate the significance of clinical risk factors immunoarchitectural patterns (IAPs) for all stages pediatric adult patients with NLPHL.
AIM. To determine the optimal strategy of chemotherapy for patients with relapsed/refractory (r/r) primary mediastinal (thymic) large B-cell lymphoma (PMBCL). MATERIALS & METHODS. The study is based on clinical data from 26 r/r PMBCL treated at NN Blokhin National Medical Cancer Research Center 2010 to 2024. were 20–48 years age (median 33 years); there 21 (81 %) women. All had a bulky tumor mass (> 10 cm in maximum dimension). RESULTS. calculations performed combined group (n = 26)...
Introduction . Over the past decades, a number of classifications and their updates have been developed for acute myeloid leukemia (AML) myelodysplastic syndromes (MDS). Myeloid neoplasms (MN) after previous therapy other diseases had different designations. The fifth edition WHO classification provides most accurate definition these neoplasmes — MN post cytotoxic (MN-pCT). problem choosing is largely related to treatment first oncological disease. Aim : present difficulties classifying...
Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) consist of cell or LP-cell. Despite their origin from active germinal centers, in some cases LP-cells express IgD, which is characteristic naive B-lymphocytes the mantle zone. Due to rarity NLPHL, assessing frequency IgD-positive difficult. This marker can serve not only for differential diagnosis with other diseases, but also indicate possible heterogeneity currently represented by six immunoarchitectural patterns.
In recent years, there has been a trend towards de-escalation of therapy in patients with early stages nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) which enables reduction the frequency late effects chemo- and radiation while still maintaining their effectiveness. Patients stage I NLPHL only require excisional biopsy lymph nodes. If complete remission cannot be achieved by surgery alone or if have II NLPHL, 3 cycles low-dose CVP (cyclophosphamide, vinblastine, prednisolone)...
Undifferentiated pleomorphic sarcoma (UPS) is a highly malignant mesenchymal tumor that ranks as one of the most common types soft tissue sarcoma. Even though chemotherapy increases 5-year survival rate in UPS, high heterogeneity frequently leads to resistance and consequently recurrences. In this study, we characterized cell composition transcriptional profile UPS with at single resolution.
Aim. To determine an optimal amount of program therapy for patients with local (I/II) stages newly diagnosed classical Hodgkin lymphoma (cHL) who are stratified into prognostic groups by different risk factors (RF).
 Materials & Methods. The present study is based on the clinical data from 125 cHL. All them were treated at NN Blokhin National Medical Cancer Research Center 2000 to 2022. aged 18–67 years (median 29 years), most women (n = 90; 72 %). 3 respect following RFs:...
Burkitt lymphoma (BL) is one of the most common types non-Hodgkin in children. The application modern risk-adapted treatment regimens has resulted 85–90 % survival rates affected patients; however, prognosis still remains poor case relapsed/refractory disease. In standard protocols, patients were stratified into risk groups based primarily on disease stage and extent lactate dehydrogenase levels. Mutations TP53 gene are associated with a many tumors, lately there have been reports that...
Nodular lymphocyte predominant Hodgkin lymphoma (NLHLP) – B-cell lymphoma, which has been historically added to the group of Hodgkin's lymphomas, despite peculiarities clinical course, treatment and prognosis, as well morphological immunophenotypical differences. In 75% cases, disease is detected at early stages (I–II according Ann Arbor classification), an indolent course a favorable prognosis with 10-years overall survival rate, more than 80%. Despite this, long-term follow-up development...
Lymphocyte-predominant Hodgkin's lymphoma (NLPHL) is a unique variant of (LH) with relatively good prognosis. The tumor differs markedly from classic LH and one the forms B cell lymphoma. Despite indolent course, it has tendency to multiple often late relapses. Microscopically, 6 distinguishable morphological patterns. prevalence in all age groups, most original studies were performed among adult patients, while there are only several publications children's population. aim this study –...
Progressive transformation of germinal centers (PTGC) is a benign reactive lymphadenopathy, which can be an independent disease or occur in association with other lymphomas, the most common variant nodular lymphocyte predominant Hodgkin lymphoma (NLPHL). To date, it has not been definitively clarified how PTGC and NLPHL are interconnected, despite abundance works presented on this topic. may precede NLPHL, synchronously it, develop after course therapy patients NLPHL. Despite similar...
The effectiveness of treatment for children with B-cell non-Hodgkin lymphomas (B-NHL) has reached 85–90% after the introduction modern risk-adapted regimens that involve risk group stratification based on tumor stage. Bone marrow involvement is traditionally evaluated using quantitative morphological analysis cells which has, however, a lower sensitivity compared to molecular genetic methods. In our study, we used next generation sequencing (NGS) identify tumor-specific...
Introduction: Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare entity. Studies evaluating outcomes for patients of all ages with scoring immunoarchitectural patterns (IAPs) are needed to inform optimal management. We sought perform an international multicenter study pediatric and adult stages NLPHL develop prognostic model assess the impact IAP. Methods: Thirty-seven centers participated in Global nLPHL One Working Group (GLOW) retrospectively identify cases diagnosed from...
In 2022, central nervous system (CNS) tumor with BCOR internal tandem duplication (BCOR ITD) was included in the fifth edition of World Health Organization Classification Tumors CNS as part embryonal group. The identification a distinct DNA methylation profile and presence recurrent genetic aberration – ITD made it possible to recognize these tumors separate entity. most cases, occur children under 5 years age are located hemispheres cerebellum or brain. Since is rare relatively new entity,...
B-cell lymphoma, unclassifiable, with features intermediate between diffuse large lymphoma (DLBCL) and classical Hodgkin’s (cHL) is a rare malignant disease that develops from mature B cells. This was first recognized as distinct entity in 2008. It most common the 20 to 40 age group children. Currently, there are no clear criteria for diagnosis standard therapy such patients. According literature, it possible use treatment regimens applied both aggressive lymphomas Hodgkin's lymphoma. The...
Background: Reduced-intensity rituximab-based therapy leads to long-term remission in more than 80-85% of pediatric patients with B-cell non-Hodgkin lymphoma (B-NHL), but case relapse or refractoriness the prognosis poor less then 20% survival rate. Therefore, identification adverse prognostic factors is critically important. Recent data show that status TP53 gene may be value children B-NHL. We evaluated clinical significance abnormalities B-NHL enrolled Russian-Belorussian B-NHL-2010mab...